Hostname: page-component-6bf8c574d5-h6jzd Total loading time: 0.001 Render date: 2025-02-14T10:29:37.973Z Has data issue: false hasContentIssue false
  • English
  • Français

New drugs and the NHS

Published online by Cambridge University Press:  02 January 2018

John Kellett
John Kellett*
Affiliation:
The Chalet Mount Gardens, London SE26 4NY
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Information
Psychiatric Bulletin , Volume 23 , Issue 2 , February 1999 , pp. 115 - 116
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1999 The Royal College of Psychiatrists

References

Goodkin, D. E. (1998) Interferon beta therapy for multiple sclerosis. Lancet, 352, 1486–1487.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.